Recently, the Conference of Top 10 Academic Advances in Traditional Chinese Medicine in 2022 organized by China Association of Chinese Medicine was held in Beijing, and NJUCM's Sino-French International Collaborative Clinical Study - High-Quality Evidence of Abelmoschus Manihot for Reduction of Albuminuria in Patients With Type 2 Diabetes and Diabetic Kidney Disease was selected as the only international research project.
The selected project
A multicenter randomized double-blind parallel controlled clinical trial on Abelmoschus manihot for the treatment of albuminuria in patients with diabetic kidney disease (DKD) was conducted by Prof. Sun Wei's team at NJUCM’s affiliated hospital (Jiangsu Province Hospital of Chinese Medicine), with Isabelle Tostivint’s team at Pitié-Salpêtrière Hospital, a public hospital in Paris. The results show that the efficacy of Huangkui capsule is comparable to and more advantageous than Irbesartan in the treatment of ACR of DKD patients, and that the combination of the two is more effective, providing a new treatment option for DKD patients with albuminuria. The study was published in Diabetes Care in 2022.
It is reported that Huangkui capsule is developed by SUZHONG PHARMA based on the clinical application of in-hospital preparations for more than 20 years, with the efficacy of eliminating dampness and heat, detoxification and disinfection, and can effectively treat chronic kidney disease, etc. Since its launch, a number of high-quality evidence-based studies have been conducted, and the research results have been published in various high impact factor journals such as AJKD.